CYP cynata therapeutics limited

What questions do holders want asked at the AGM?, page-92

  1. 1,020 Posts.
    lightbulb Created with Sketch. 401
    I listened as was very impressed with how Ross in particular presented. I didn't ask any questions ultimately as the concerns I had were addressed in the presentation. My key notes were:

    1. Lessons learnt from MEND trial - extensive DD being done to ensure hospitals can actually recruit patients in GvHD trial.
    2. “Anticipate further corporate partnerships over the course of the year” - specifically referring to IPF, Respiratory and CLI.
    3. Very clear explanation of the Cymerus process and it’s advantages over conventionally derived MSC’s. Makes it an easy sell, and the FDA clearly also agree, hence only 30 days for IND approval (Ross confirmed this during the meeting).

    In summary, this was a very persuasive presentation. Ross conveyed an urgency to ink a partnership (or multiple) over the next year which I haven't seen previously, and ultimately this coupled with the known catalysts from clinical trial data will drive the value of Cynata.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
0.015(9.68%)
Mkt cap ! $38.41M
Open High Low Value Volume
15.5¢ 17.0¢ 15.5¢ $47.10K 289.1K

Buyers (Bids)

No. Vol. Price($)
1 50000 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 23813 3
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.